Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-155-3p
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
NT21MP
Downstream target
CXCR4
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Paclitaxel
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
These findings suggested that miR-155-3p/5p and their target genes MYD88 and TP53INP1 may serve as novel biomarkers for NT21MP therapy through the CXCR4 pathway for improving sensitivity to paclitaxel in breast cancer.
Tissue resource
human breast cancer cell lines MCF-7
human breast cancer cell lines MCF-7
Experiment
qRT-PCR,Western blot
Institute
the Shanghai Cell Institute of Chinese Academy of Science
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.